1
|
Li X, Du H, Zhan S, Liu W, Wang Z, Lan J, PuYang L, Wan Y, Qu Q, Wang S, Yang Y, Wang Q, Xie F. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1+ regulator B cells mediates immunosuppression in triple-negative breast cancer. Front Immunol 2022; 13:830606. [PMID: 35935985 PMCID: PMC9354578 DOI: 10.3389/fimmu.2022.830606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Accepted: 06/28/2022] [Indexed: 11/24/2022] Open
Abstract
Accumulating evidence suggests that regulatory B cells (Bregs) play important roles in inhibiting the immune response in tumors. Programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) are important molecules that maintain the balance of the immune response and immune tolerance. This study aims to evaluate the soluble form of PD-L1 and its function in inducing the differentiation of B lymphocytes, investigate the relationship between soluble PD-L1 (sPD-L1) and B-cell subsets, and explore the antitumor activity of T lymphocytes after PD-L1 blockade in coculture systems. In an effort to explore the role of sPD-L1 in human breast cancer etiology, we examined the levels of sPD-L1 and interleukin-10 (IL-10) in the serum of breast tumor patients and the proportions of B cells, PD-1+ B cells, Bregs, and PD-1+ Bregs in the peripheral blood of patients with breast tumors and assessed their relationship among sPD-L1, IL-10, and B-cell subsets. The levels of sPD-L1 and IL-10 in serum were found to be significantly higher in invasive breast cancer (IBCa) patients than in breast fibroadenoma (FIBma) patients. Meanwhile, the proportions and absolute numbers of Bregs and PD-1+ Bregs in the peripheral blood of IBCa patients were significantly higher than those of FIBma patients. Notably, they were the highest in triple-negative breast cancer (TNBC) among other subtypes of IBCa. Positive correlations of sPD-L1 and IL-10, IL-10 and PD-1+ Bregs, and also sPD-L1 and PD-1+ Bregs were observed in IBCa. We further demonstrated that sPD-L1 could induce Breg differentiation, IL-10 secretion, and IL-10 mRNA expression in a dose-dependent manner in vitro. Finally, the induction of regulatory T cells (Tregs) by Bregs was further shown to suppress the antitumor response and that PD-L1 blockade therapies could promote the apoptosis of tumor cells. Together, these results indicated that sPD-L1 could mediate the differentiation of Bregs, expand CD4+ Tregs and weaken the antitumor activity of CD4+ T cells. PD-L1/PD-1 blockade therapies might be a powerful therapeutic strategy for IBCa patients, particularly for TNBC patients with high level of PD-1+ Bregs.
Collapse
Affiliation(s)
- Xuejiao Li
- School of Biology & Basic Medical Sciences, Medical College of Soochow University, Suzhou, China
- Department of Pathology, The First People’s Hospital of Lianyungang, Lianyungang, China
| | - Huan Du
- School of Biology & Basic Medical Sciences, Medical College of Soochow University, Suzhou, China
- Department of Pathology, Huashan Hospital, Fudan University, Shanghai, China
| | - Shenghua Zhan
- Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Wenting Liu
- School of Biology & Basic Medical Sciences, Medical College of Soochow University, Suzhou, China
- Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Zhangyu Wang
- Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China
- Department of General Surgery, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, China
| | - Jing Lan
- Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Longxiang PuYang
- School of Biology & Basic Medical Sciences, Medical College of Soochow University, Suzhou, China
| | - Yuqiu Wan
- School of Biology & Basic Medical Sciences, Medical College of Soochow University, Suzhou, China
- Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Qiuxia Qu
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, China
| | - Sining Wang
- School of Biology & Basic Medical Sciences, Medical College of Soochow University, Suzhou, China
| | - Yang Yang
- School of Biology & Basic Medical Sciences, Medical College of Soochow University, Suzhou, China
| | - Qin Wang
- School of Biology & Basic Medical Sciences, Medical College of Soochow University, Suzhou, China
- *Correspondence: Fang Xie, ; Qin Wang,
| | - Fang Xie
- School of Biology & Basic Medical Sciences, Medical College of Soochow University, Suzhou, China
- *Correspondence: Fang Xie, ; Qin Wang,
| |
Collapse
|
2
|
Ohe G, Kudo Y, Kamada K, Mouri Y, Takamaru N, Kudoh K, Kurio N, Miyamoto Y. The Soluble Factor from Oral Cancer Cell Lines Inhibits Interferon-γ Production by OK-432 via the CD40/CD40 Ligand Pathway. Cancers (Basel) 2021; 13:cancers13133301. [PMID: 34209347 PMCID: PMC8269085 DOI: 10.3390/cancers13133301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Revised: 06/20/2021] [Accepted: 06/28/2021] [Indexed: 11/16/2022] Open
Abstract
(1) Background: OK-432 is a penicillin-killed, lyophilized formulation of a low-toxicity strain (Su) of Streptococcus pyogenes (Group A). It is a potent immunotherapy agent for several types of cancer, including oral cancer. We previously showed that (i) OK-432 treatment induces a high amount of IFN-? production from peripheral blood mononuclear cells (PBMCs), and (ii) conditioned medium (CM) from oral cancer cells suppresses both the IFN-? production and cytotoxic activity of PBMCs driven by OK-432. The aim of this study was to determine the inhibitory mechanism of OK-432-induced IFN-? production from PBMCs by CM. (2) Methods: We performed cDNA microarray analysis, quantitative RT-PCR, and ELISA to reveal the inhibitory mechanism of CM. (3) Results: We found that CD40 plays a key role in IFN-? production via IL-12 production. Although OK-432 treatment upregulated the expression levels of the IL-12p40, p35, and CD40 genes, CM from oral cancer cells downregulate these genes. The amount of IFN-? production by OK-432 treatment was decreased by an anti-CD40 neutralizing antibody. (4) Conclusions: Our study suggests that uncertain soluble factor(s) produced from oral cancer cells may inhibit IFN-? production from PBMCs via suppressing the CD40/CD40L-IL-12 axis.
Collapse
Affiliation(s)
- Go Ohe
- Department of Oral Surgery, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan; (K.K.); (N.T.); (K.K.); (N.K.); (Y.M.)
- Dentistry and Oral Surgery, Takamatsu Municipal Hospital, 847-1 Ko Busshozan-cho, Takamatsu 761-8538, Japan
- Correspondence:
| | - Yasusei Kudo
- Department of Oral Bioscience, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan; (Y.K.); (Y.M.)
| | - Kumiko Kamada
- Department of Oral Surgery, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan; (K.K.); (N.T.); (K.K.); (N.K.); (Y.M.)
| | - Yasuhiro Mouri
- Department of Oral Bioscience, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan; (Y.K.); (Y.M.)
| | - Natsumi Takamaru
- Department of Oral Surgery, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan; (K.K.); (N.T.); (K.K.); (N.K.); (Y.M.)
| | - Keiko Kudoh
- Department of Oral Surgery, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan; (K.K.); (N.T.); (K.K.); (N.K.); (Y.M.)
| | - Naito Kurio
- Department of Oral Surgery, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan; (K.K.); (N.T.); (K.K.); (N.K.); (Y.M.)
| | - Youji Miyamoto
- Department of Oral Surgery, Tokushima University Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8504, Japan; (K.K.); (N.T.); (K.K.); (N.K.); (Y.M.)
| |
Collapse
|
3
|
Guan H, Lan Y, Wan Y, Wang Q, Wang C, Xu L, Chen Y, Liu W, Zhang X, Li Y, Gu Y, Wang Z, Xie F. PD-L1 mediated the differentiation of tumor-infiltrating CD19 + B lymphocytes and T cells in Invasive breast cancer. Oncoimmunology 2015; 5:e1075112. [PMID: 27057444 DOI: 10.1080/2162402x.2015.1075112] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 07/14/2015] [Accepted: 07/15/2015] [Indexed: 10/23/2022] Open
Abstract
Accumulating evidence suggests that B cells play important roles in inhibiting the immune response in autoimmune disorders and human tumors as well as murine tumor models. In an effort to explore the role of B cells in human breast cancer etiology, we examined the presence of CD19+ B lymphocytes in 134 cases of invasive breast carcinoma (IBCa) and 31 breast fibroadenoma, and assessed its relationship with PD-L1 (programmed death-ligand 1) expression in breast cancer. We found that the density of CD19+ B lymphocytes was higher in IBCa compared with fibroadenoma, and significantly associated with increasing tumor grade, negative estrogen status. Similar findings were observed for the expression of IL-10 in IBCa. Meanwhile, CD19+ B lymphocytes were shown to be highly coincident with PD-L1 and IL-10 in IBCa. We further demonstrated that CD19+ B cells can differentiate into CD19+CD24+CD38+ B cells when co-cultured with PD-L1hi MDA-MB231 cells. In addition, the percentage of CD19+CD24+CD38+ B cells was higher in breast tissue and peripheral blood cells of IBCa patients than that of benign tumor and health individuals. And CD19+CD24+CD38+ B cells were found to be IL-10 secreting B cells. Finally, we showed that CD19+ B cells from IBCa patients but not healthy individuals induced formation of CD4+CD25+Foxp3+ T cells when co-cultured with T cells from IBCa patients and healthy subjects (80.4% and 30.8% respectively). The induction of CD4+CD25+Foxp3+ T cells by CD19+ B cells was further shown to be mediated by PD-L1. Together, these results are suggestive of a role for CD19+ B lymphocytes in immune suppression and tumor evasion via PD-L1 in breast cancer.
Collapse
Affiliation(s)
- Honggeng Guan
- Department of General Surgery, The First Affiliated Hospital of Soochow University , Suzhou, P.R. China
| | - Yang Lan
- Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, P.R. China; Department of General Surgery, Wuxi Third People's Hospital, Wuxi, P. R. China
| | - Yuqiu Wan
- Department of General Surgery, The First Affiliated Hospital of Soochow University , Suzhou, P.R. China
| | - Qin Wang
- Department Immunology, Medical College of Soochow University , Suzhou, P. R. China
| | - Cheng Wang
- The Ultrasonagraphy Center of the Second Affiliated Hospital of Soochow University , Suzhou, P. R. China
| | - Longjiang Xu
- The Second Affiliated Hospital of Soochow University , Suzhou, P. R. China
| | - Yongjing Chen
- Department Immunology, Medical College of Soochow University , Suzhou, P. R. China
| | - Wenting Liu
- Department of Pathology, Medical College of Soochow University , Suzhou, P. R. China
| | - Xueguang Zhang
- Jiangsu stem cell lab center , Jiangsu, Suzhou, P. R. China
| | - Yecheng Li
- The Second Affiliated Hospital of Soochow University , Suzhou, P. R. China
| | - Yongping Gu
- Department of Pathology, Medical College of Soochow University , Suzhou, P. R. China
| | - Zemin Wang
- Department of Environmental Health, School of Public Health, Indiana University , Bloomington, IN, USA
| | - Fang Xie
- Department of Pathology, Medical College of Soochow University , Suzhou, P. R. China
| |
Collapse
|
4
|
Chowdhury F, Johnson PW, Glennie M, Williams AP. Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial. Cancer Immunol Res 2014; 2:229-40. [PMID: 24778319 PMCID: PMC4007630 DOI: 10.1158/2326-6066.cir-13-0070] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Immunostimulatory antibodies entering the clinic create challenge in terms of not only pharmacodynamics for monitoring anticipated mechanisms but also predetermining cytotoxicity. We show the use of ex vivo whole-blood samples to predict the activation requirements, cytokine signature, and adverse events of an anti-human-CD40 chimeric IgG1 antibody, ChiLob 7/4. Assessments were initially undertaken on human myeloid (mDC1) and plasmacytoid (pDC) dendritic cells, in which an absolute need for cross-linking was shown through the upregulation of activation markers CD83 and CCR7. Subsequent cytokine secretion evaluations of ex vivo whole blood showed the cross-linked antibody-induced increases in MIP1β, interleukin (IL)-8, IL-12, TNFα, and IL-6. This cytokine signature compared favorably with the Toll-like receptor (TLR) ligand lipopolysaccharide (LPS), in which levels of TNFα and IL-6 were significantly higher, suggesting a less intense proinflammatory response and possible modified cytokine release syndrome when used in human trials. Following first-in-human use of this agent within a dose escalation study, in vivo evaluations of dendritic cell activation and secreted cytokines closely matched the predetermined immunomonitoring endpoints. Patients showed a comparable pattern of MIP1β, IL-8, and IL-12 secretion, but no TNFα and IL-6 were identified. Mild symptoms relating to a cytokine release syndrome were seen at an equivalent dosage to that observed for dendritic cell activation and cytokine release. In summary, ChiLob 7/4 induces a distinctive pattern of dendritic cell activation and cytokine secretion in ex vivo assays that can be predictive of in vivo responses. Such preclinical approaches to monoclonal antibody evaluation may inform both the starting dosages and the anticipated cytokine release events that could occur, providing a valuable adjunct for future first-in-human assessments of immunostimulatory antibodies.
Collapse
Affiliation(s)
- F. Chowdhury
- Academic Unit of Cancer Sciences Unit, Faculty of Medicine, CRUK Clinical Centre, Somers Cancer Research Building, University of Southampton, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, England
- Southampton NIHR Experimental Cancer Medicine Centre, Mailpoint 824, Southampton, SO16 6YD, England
| | - P. W. Johnson
- Academic Unit of Cancer Sciences Unit, Faculty of Medicine, CRUK Clinical Centre, Somers Cancer Research Building, University of Southampton, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, England
- Southampton NIHR Experimental Cancer Medicine Centre, Mailpoint 824, Southampton, SO16 6YD, England
| | - M.J. Glennie
- Academic Unit of Cancer Sciences Unit, Faculty of Medicine, CRUK Clinical Centre, Somers Cancer Research Building, University of Southampton, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, England
| | - A. P. Williams
- Academic Unit of Cancer Sciences Unit, Faculty of Medicine, CRUK Clinical Centre, Somers Cancer Research Building, University of Southampton, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, England
- Southampton NIHR Experimental Cancer Medicine Centre, Mailpoint 824, Southampton, SO16 6YD, England
| |
Collapse
|
5
|
Atanasova M, Whitty A. Understanding cytokine and growth factor receptor activation mechanisms. Crit Rev Biochem Mol Biol 2012; 47:502-30. [PMID: 23046381 DOI: 10.3109/10409238.2012.729561] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
Our understanding of the detailed mechanism of action of cytokine and growth factor receptors - and particularly our quantitative understanding of the link between structure, mechanism and function - lags significantly behind our knowledge of comparable functional protein classes such as enzymes, G protein-coupled receptors, and ion channels. In particular, it remains controversial whether such receptors are activated by a mechanism of ligand-induced oligomerization, versus a mechanism in which the ligand binds to a pre-associated receptor dimer or oligomer that becomes activated through subsequent conformational rearrangement. A major limitation to progress has been the relative paucity of methods for performing quantitative mechanistic experiments on unmodified receptors expressed at endogenous levels on live cells. In this article, we review the current state of knowledge on the activation mechanisms of cytokine and growth factor receptors, critically evaluate the evidence for and against the different proposed mechanisms, and highlight other key questions that remain unanswered. New approaches and techniques have led to rapid recent progress in this area, and the field is poised for major advances in the coming years which promise to revolutionize our understanding of this large and biologically and medically important class of receptors.
Collapse
Affiliation(s)
- Mariya Atanasova
- Department of Chemistry, Boston University, Boston, MA 02215, USA
| | | |
Collapse
|
6
|
Huang Q, Qu QX, Xie F, Hu JM, Chen YG, Zhang XG. Sensitization of SiHa cell to gemcitabine by CD40 activation and its overexpression in cervical carcinoma. Med Oncol 2010; 28:781-8. [PMID: 20467921 DOI: 10.1007/s12032-010-9538-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2010] [Accepted: 04/08/2010] [Indexed: 11/30/2022]
Abstract
CD40, a member of the tumor necrosis factor receptor superfamily, is widely expressed on various cell types. Some studies show that CD40 expression is related to several carcinomas, where its function remains largely unknown. This study investigated the expression of CD40 on cervical carcinoma and evaluated the effect of agnostic anti-CD40 mAb (5C11) on tumor cell line (SiHa). CD40 expression on the primary cervical carcinoma samples was detected by immunohistochemistry. Results showed that CD40 is commonly expressed in human cervical carcinoma, which is higher than that of normal cervix, cervical precancerous tissue and chronic cervicitis. Treatment of the SiHa cell with the agonistic anti-CD40 monoclonal antibody or Gemcitabine alone did not inhibit the proliferation of the SiHa cell in vitro, but the activation of CD40 on SiHa could enhance its sensitivity to Gemcitabine. Furthermore, CD40 activation blocked SiHa in the S phase, stimulated proapoptotic Bax and inhibited antiapoptotic Bcl-XL mRNA synthesis in the SiHa cell. Apoptosis in SiHa was associated with an increasing ratio of Bax to Bcl-XL in mRNA levels. It is concluded that use of the anti-CD40 mAb 5C11 in combination with chemotherapy may have significant therapeutic potential.
Collapse
Affiliation(s)
- Qin Huang
- Clinical Immunology Laboratory, The First Affiliated Hospital of Soochow University, 188# Shizi Street, 215006, Suzhou, China
| | | | | | | | | | | |
Collapse
|
7
|
Zhang G, Hou J, Shi J, Yu G, Lu B, Zhang X. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 2008; 123:538-46. [PMID: 18194267 DOI: 10.1111/j.1365-2567.2007.02723.x] [Citation(s) in RCA: 136] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Expression of membrane CD276 (mB7-H3) has been reported on dendritic cells (DCs), monocytes, activated T cells, and various carcinoma cells. However, reports concerning its in vivo function have been inconsistent. Moreover, whether there is a soluble form of this protein is not known. In this study, using a sensitive dual monoclonal antibody sandwich enzyme-linked immunosorbent assay (ELISA) to detect the soluble form of B7-H3 (sB7-H3), we demonstrated the release of sB7-H3 by monocytes, DCs, activated T cells, and various mB7-H3+ but not mB7-H3- carcinoma cells. Release from cells was blocked by addition of a matrix metalloproteinase inhibitor (MMPI), which concomitantly caused the accumulation of B7-H3 on the cell surface. To determine the level of circulating sB7-H3, more than 200 serum samples were included in the study. The results indicated that sB7-H3 was present at high levels in all serum samples. Western blotting of sB7-H3 from cell culture supernatants or sera of healthy donors indicated that the molecular size was approximately 16 kDa. Soluble B7-H3 was able to bind to the B7-H3 receptor (B7-H3R) on activated T cells, which showed that sB7-H3 is a functionally active form. These results indicate that release of sB7-H3 from the cell surface is mediated by a matrix metalloproteinase and probably regulates B7-H3R/B7-H3 interactions in vivo. Cleavage of sB7-H3 to an active soluble form would alter both proximal and distal cellular responses.
Collapse
Affiliation(s)
- Guangbo Zhang
- Clinical Immunology Laboratory, Suzhou University no. 1 Affiliated Hospital, Suzhou, China
| | | | | | | | | | | |
Collapse
|